Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study.
Adamo V, Ricciardi GRR, Giuffrida D, Scandurra G, Russo A, Blasi L, Spadaro P, Iacono C, Soto Parra HJ, Savarino A, Ferraú F, Zerilli F, Verderame F, Butera A, Santangelo C, Franchina V, Caruso M.
Adamo V, et al. Among authors: ricciardi grr.
Ther Adv Med Oncol. 2019 Dec 19;11:1758835919895755. doi: 10.1177/1758835919895755. eCollection 2019.
Ther Adv Med Oncol. 2019.
PMID: 31903098
Free PMC article.